Sign In
Buy ZNTL
$4.74
-0.180 (-3.66%)
At Close: Jul 31, 2026
Zentalis: A Buy As Small Molecule Trials Continue To Advance
09:42am, Thursday, 24'th Aug 2023
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's financials show a solid cash position and efficient allocation of
Matrix Capital Infuses $108 Million Into Zentalis Toward Promising Cancer Therapeutics
10:21pm, Thursday, 22'nd Jun 2023
Shares of Zentalis Pharmaceuticals Inc (US:ZNTL) are cooling off a bit Thursday after yesterday's 4% rise capped a five-day rally of 17.8%.
Why Shares of Zentalis Pharmaceuticals Dropped This Week
02:34pm, Friday, 02'nd Jun 2023
Zentalis is a clinical-stage biotech that is focusing on cancer therapies. The stock is up more than 29% this year.
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatmen
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
07:01am, Wednesday, 01'st Feb 2023
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically dif
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
07:00am, Wednesday, 31'st Aug 2022
NEW YORK and SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically dif
Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know
01:33pm, Friday, 26'th Aug 2022
Zentalis Pharmaceuticals, Inc. (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season
09:47am, Wednesday, 10'th Aug 2022
Zentalis Pharmaceuticals (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer Injects $25M Via Equity In Zentalis Pharma
10:19am, Wednesday, 27'th Apr 2022
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million. The offering is expected to close by April 29.
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks
11:17am, Tuesday, 19'th Apr 2022
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
04:01pm, Wednesday, 09'th Mar 2022
NEW YORK and SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecul
Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022
04:30pm, Tuesday, 08'th Mar 2022
Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will be presented during a mini symposium session Updated data from Phase 1 expansion cohort of ZN-c3 in uterine s
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
07:00am, Thursday, 03'rd Feb 2022
NEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule
Initial results are expected in 2H 2022 Initial results are expected in 2H 2022
NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecul
